Six Teams to Study Managed Care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

Six research teams will receive a total of $8.5 million. The teams will be led by Jose Escarce, MD, PhD, of RAND, Santa Monica, Calif; Edward Guadagnoli, PhD, Harvard Medical School; Katherine Kahn, MD, University of California, Los Angeles; Tracy Lieu, MD, Kaiser Permanente of Northern California, Oakland; Barbara McNeil, MD; Harvard Medical School; and Elizabeth Shenkman, PhD, University of Florida, Gainesville.

The three sponsoring organizations are the Agency for Health Care Policy and Research (AHCPR) and the Health Resources and Services Administration, both parts of the HSS, and the American Association of Health Plans Foundation, which provides research for the nation’s largest managed care

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content